Clubbed thiazoles by MAOS: a novel approach to cyclin-dependent kinase 5/p25 inhibitors as a potential treatment for Alzheimer's disease.
A novel clubbed triazolyl thiazole series of cdk5/p25 inhibitors, potentially useful for the treatment of Alzheimer's disease, is disclosed. Evaluation of the SAR of substitution within these series has allowed the identification of a range of compounds which significantly reduce brain cdk5/p25 and thus have potential as possible treatments for Alzheimer's disease.
Shiradkar
Mahendra Ramesh
MR
Dr. Reddys Laboratories, 7-1-27 Ameerpet, Hyderabad 16, Andhra Pradesh, India. rrshiradkar@rediffmail.com
Akula
Kalyan Chakravarthy
KC
Dasari
Varaprasad
V
Baru
Vijayakumar
V
Chiningiri
Bhoomeshwar
B
Gandhi
Santosh
S
Kaur
Ranjit
R
D000544:Alzheimer Disease / Q000188:drug therapy*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D002522:Chlorocebus aethiops; D051360:Cyclin-Dependent Kinase 5 / Q000037:antagonists & inhibitors*; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology* / Q000627:therapeutic use; D007202:Indicators and Reagents; D009682:Magnetic Resonance Spectroscopy; D008872:Microwaves; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000138:chemical synthesis* / Q000494:pharmacology*; D014709:Vero Cells
D004791:Enzyme Inhibitors; D007202:Indicators and Reagents; D013844:Thiazoles; D051360:Cyclin-Dependent Kinase 5